Bayesian Design in Clinical Trials
In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Nowadays, regulatory authorities appear to be more receptive to Bayesian methods than ever. The Bayesian methodology is well suited to address the issues arising in the planning, analysis, and conduct of...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (190 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545956604498 |
---|---|
ctrlnum |
(CKB)5400000000045321 (oapen)https://directory.doabooks.org/handle/20.500.12854/79674 (EXLCZ)995400000000045321 |
collection |
bib_alma |
record_format |
marc |
spelling |
Berchialla, Paola edt Bayesian Design in Clinical Trials Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (190 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Open access Unrestricted online access star In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Nowadays, regulatory authorities appear to be more receptive to Bayesian methods than ever. The Bayesian methodology is well suited to address the issues arising in the planning, analysis, and conduct of clinical trials. Due to their flexibility, Bayesian design methods based on the accrued data of ongoing trials have been recommended by both the US Food and Drug Administration and the European Medicines Agency for dose-response trials in early clinical development. A distinctive feature of the Bayesian approach is its ability to deal with external information, such as historical data, findings from previous studies and expert opinions, through prior elicitation. In fact, it provides a framework for embedding and handling the variability of auxiliary information within the planning and analysis of the study. A growing body of literature examines the use of historical data to augment newly collected data, especially in clinical trials where patients are difficult to recruit, which is the case for rare diseases, for example. Many works explore how this can be done properly, since using historical data has been recognized as less controversial than eliciting prior information from experts’ opinions. In this book, applications of Bayesian design in the planning and analysis of clinical trials are introduced, along with methodological contributions to specific topics of Bayesian statistics. Finally, two reviews regarding the state-of-the-art of the Bayesian approach in clinical field trials are presented. English Humanities bicssc Social interaction bicssc dose-escalation combination study modelling assumption interaction adaptive designs adaptive randomization Bayesian designs clinical trials predictive power target allocation Bayesian inference highest posterior density intervals normal approximation predictive analysis sample size determination bayesian meta-analysis clustering binary data priors frequentist validation Bayesian rare disease prior distribution meta-analysis sample size bridging studies distribution distance oncology phase I dose-finding dose–response bayesian inference prior elicitation latent dirichlet allocation clinical trial power-prior poor accrual Bayesian trial cisplatin doxorubicin oxaliplatin dose escalation PIPAC peritoneal carcinomatosis randomized controlled trial causal inference doubly robust estimation propensity score Bayesian monitoring futility rules interim analysis posterior and predictive probabilities stopping boundaries Bayesian trial design early phase dose finding treatment combinations optimal dose combination 3-0365-3333-8 Baldi, Ileana edt Berchialla, Paola oth Baldi, Ileana oth |
language |
English |
format |
eBook |
author2 |
Baldi, Ileana Berchialla, Paola Baldi, Ileana |
author_facet |
Baldi, Ileana Berchialla, Paola Baldi, Ileana |
author2_variant |
p b pb i b ib |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Bayesian Design in Clinical Trials |
spellingShingle |
Bayesian Design in Clinical Trials |
title_full |
Bayesian Design in Clinical Trials |
title_fullStr |
Bayesian Design in Clinical Trials |
title_full_unstemmed |
Bayesian Design in Clinical Trials |
title_auth |
Bayesian Design in Clinical Trials |
title_new |
Bayesian Design in Clinical Trials |
title_sort |
bayesian design in clinical trials |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (190 p.) |
isbn |
3-0365-3333-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT berchiallapaola bayesiandesigninclinicaltrials AT baldiileana bayesiandesigninclinicaltrials |
status_str |
n |
ids_txt_mv |
(CKB)5400000000045321 (oapen)https://directory.doabooks.org/handle/20.500.12854/79674 (EXLCZ)995400000000045321 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Bayesian Design in Clinical Trials |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1797875413795471360 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04586nam-a2201009z--4500</leader><controlfield tag="001">993545956604498</controlfield><controlfield tag="005">20240430192558.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202203s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045321</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/79674</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045321</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Berchialla, Paola</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bayesian Design in Clinical Trials</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (190 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Nowadays, regulatory authorities appear to be more receptive to Bayesian methods than ever. The Bayesian methodology is well suited to address the issues arising in the planning, analysis, and conduct of clinical trials. Due to their flexibility, Bayesian design methods based on the accrued data of ongoing trials have been recommended by both the US Food and Drug Administration and the European Medicines Agency for dose-response trials in early clinical development. A distinctive feature of the Bayesian approach is its ability to deal with external information, such as historical data, findings from previous studies and expert opinions, through prior elicitation. In fact, it provides a framework for embedding and handling the variability of auxiliary information within the planning and analysis of the study. A growing body of literature examines the use of historical data to augment newly collected data, especially in clinical trials where patients are difficult to recruit, which is the case for rare diseases, for example. Many works explore how this can be done properly, since using historical data has been recognized as less controversial than eliciting prior information from experts’ opinions. In this book, applications of Bayesian design in the planning and analysis of clinical trials are introduced, along with methodological contributions to specific topics of Bayesian statistics. Finally, two reviews regarding the state-of-the-art of the Bayesian approach in clinical field trials are presented.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Humanities</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Social interaction</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dose-escalation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combination study</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">modelling assumption</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adaptive designs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adaptive randomization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bayesian designs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive power</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target allocation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bayesian inference</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">highest posterior density intervals</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">normal approximation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sample size determination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bayesian meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clustering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">binary data</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">priors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frequentist validation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bayesian</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rare disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prior distribution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sample size</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bridging studies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">distribution distance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phase I</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dose-finding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dose–response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bayesian inference</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prior elicitation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">latent dirichlet allocation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">power-prior</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poor accrual</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bayesian trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cisplatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">doxorubicin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxaliplatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dose escalation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PIPAC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">peritoneal carcinomatosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">randomized controlled trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">causal inference</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">doubly robust estimation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">propensity score</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bayesian monitoring</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">futility rules</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interim analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">posterior and predictive probabilities</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stopping boundaries</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bayesian trial design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">early phase dose finding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment combinations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">optimal dose combination</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3333-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baldi, Ileana</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berchialla, Paola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baldi, Ileana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-05-01 16:10:54 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338079540004498&Force_direct=true</subfield><subfield code="Z">5338079540004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338079540004498</subfield></datafield></record></collection> |